Isocitrate Dehydrogenase (IDH)
-
mutant IDH1 R132H inhibitor
Mutant IDH1 inhibitor is a potent mutant IDH1 R132H inhibitor with IC50 of < 72 nM.
了解更多
-
IDH inhibitor
Mutant IDH1-IN-2 is a inhibitor of mutant Isocitrate dehydrogenase (IDH) proteins, with IC50 of in LS-MS biochemical assay, IC50 of 16.6 nM in Fluorescence biochemical assay.
了解更多
-
mutant-selective IDH1 inhibitor
Mutant IDH1-IN-1 is a mutant-selective IDH1 inhibitor with with IC50s of 4, 42, 80 and 143 nM against mutant IDH1 R132C/R132C, IDH1 R132H/R132H, IDH1 R132H/WT and wild type IDH1, respectively.
了解更多
-
IDH1 抑制剂
AGI-5198 (IDH-C35)是一种非常有效的选择性IDH1突变抑制剂,具有潜在的抗癌活性。
了解更多
-
IDH2 R140Q 抑制剂
AGI-6780是有效的选择性IDH2突变抑制剂,IC50值为23 nM。
了解更多
-
IDH1 R132H 抑制剂
IDH-C227是一种有效的选择性IDH1 R132H抑制剂。
了解更多
-
IDH2 抑制剂
Enasidenib是一种有效的选择性IDH2抑制剂,具有潜在的抗癌活性(IDH2 =异柠檬酸脱氢酶2)。
了解更多
- Mohammed NadimSardoiwala, .et al. Hytrin loaded polydopamine-serotonin nanohybrid induces IDH2 mediated neuroprotective effect to alleviate Parkinson's disease, Materials Science and Engineering: C, 2021, Dec 24
-
IDH1 抑制剂
AG-120 (Ivosidenib)是1型异柠檬酸脱氢酶(IDH1)的口服抑制剂,具有潜在的抗肿瘤活性。
了解更多
-
IDH1 抑制剂
IDH305是柠檬酸循环酶异柠檬酸脱氢酶[NADP]细胞质的抑制剂(异柠檬酸脱氢酶1,IDH1),在残基R132(IDH1(R132))处具有突变,具有潜在的抗肿瘤活性。
了解更多
-
IDH1 抑制剂
Vorasidenib (AG-881)是一种有效且选择性的口服抑制剂,可抑制细胞质中异柠檬酸脱氢酶1型(IDH1,IDH1 [NADP+]可溶)和2型(IDH2异柠檬酸脱氢酶[NADP+])的突变形式。线粒体中的线粒体,具有潜在的抗肿瘤活性。
了解更多
-
mIDH1 抑制剂
BAY-1436032是一种有效的,选择性的,口服的突变型异柠檬酸脱氢酶1(mIDH1)抑制剂。
了解更多
-
IDH1 inhibitor
Olutasidenib is a potent, selective inhibitor of mutant Isocitrate dehydrogenase (IDH)1 for the treatment of acute myeloid leukemia.
了解更多
-
IDH1 inhibitor
Mutant IDH1-IN-4 (compound 434) is an inhibitor of mutant Isocitrate dehydrogenase 1 (IDH 1), with IC50 values of ?? 0.5 μM for mutant IDH1 in R132H, HT1080 and U87R132H cells.
了解更多
-
IDH1 inhibitor
DH1 Inhibitor 2 is a potent IDH1 inhibitor via a direct covalent modification of His315, with an IC50 of 110 nM.
了解更多